



SCL Lifesciences Limited



About Us

SCL Lifesciences is a reliable supplier and CDMO services provider for Pharmaceutical APIs and intermediates.



SCL was incorporated on 20th December 1993 as a Private Limited Company. It initially began its operations by manufacturing Intermediates. Later, on 1st July 1997, the Company was reconstituted as a Public Limited Company and subsequently was renamed to its present name. In 2004, SCL set up a new facility for API manufacturing and currently offers a wide range of APIs and Advanced Intermediates to its Customers. These APIs and Advanced Intermediates cater to diverse Therapeutic segments such as Non-Steroidal Anti- Inflammatory Drugs (NSAIDs), Cardiovascular System (CVS), Anti-Diabetes, Anti-cholinergic, Central Nervous System (CNS), Anthelmintics/Anti-filarial and Diagnostic segments such as MRI (Contrast Media).

SCL caters to both Domestic as well as International Market. It derives ~75% of the total revenue from the international market and the remaining ~25% from the Domestic market. SCL is engaged in manufacturing of Bulk Drugs/Active Pharmaceutical Ingredients (APIs) and Advanced Intermediates. We provide CDMO Services to our clients in regulated markets of Europe, USA and Japan.

SCL has over the years expanded its presence across the globe with key export markets being Europe (France, Spain, Germany, Italy, Greece, Austria, Portugal, Slovenia, Netherlands, Denmark), the United States of America (USA), Turkey, Japan, Korea, Brazil, Russia & CIS countries, South & Central America, Middle East & Northern Africa (MENA) region & other Asian countries.

The Company is headquartered at Panchkula (Haryana) near Chandigarh and has 2 Manufacturing facilities (one each for intermediates & APIs) located at Derabassi, Mohali (Punjab) about 200Kms from Delhi. Company has started a new Knowledge Centre for research and development for APIs, Intermediates, Vaccine ingredients and CRO/CDMO business at Genome Valley, Hyderabad. Marketing headquarter for the company is based out of Delhi NCR. Company is currently expanding capacity further by 120KL in the same facility including a pilot scale facility.

The Manufacturing facilities of the Company comply with the United States Food and Drug Administration (USFDA), European Union Good Manufacturing Practices (EU-GMP), TGA Australia, MFDS Korea & Japanese Pharmaceutical and Medical Devices Agency (JPMDA).

Major Milestones

BRONZE | Top 35%

ecovadis

Sustainability Rating
FEB 2026

Intermediate manufacturing
site setup

1993

Becomes India's largest supplier
of Cephalosporin & Penem
Intermediates

2002

API manufacturing site set up

2004

First EU GMP Certification of
API site, subsequent Audits in
2008, 2011, 2012, 2015 & 2024

2005

Joint Venture with Mitsubishi
Corporation, Japan

2013

First WHO Geneva GMP
approval, subsequent audits in
2016, 2018 & 2026

2014

First TGA approval, subsequent
approval in 2025, First MFDS
Approval

2015



2016

First USFDA Approval received,
First CEP

2017/
2018

Second and Third USFDA Audits
cleared

2019

PMDA Japan Audit cleared

2022

Second CEP

2023

CBPF Brazil Approval, NMPA
China Approval, Third CEP.
Introduction of new segment of
Vaccine ingredients

2024

New R&D Centre established in
Hyderabad, Fourth & Fifth CEPs

2025

Company name changed to
SCL Lifesciences Ltd.

2026

Fourth USFDA audit cleared,
Sixth CEP



CDMO Services



We are leading provider of Custom development and manufacturing services to clients across Europe, USA and Japan and have more than a decade of successful experience of delivering the services on both Contract and FTE basis.

Some references of our CDMO partnerships:

- CDMO project for advance intermediate for European innovator Company.
- Development, Scale up and Contract manufacturing of APIs for large European Generic Pharma company for more than a decade.
- CDMO project for multiple APIs with European Innovator
- CDMO project for NCE and 505(B)2 filings in US for multiple clients.
- CDMO project for Niche/Orphan products, Co-development on an end to end model, exclusive basis for US based customer. Collaborative agreement for sales in defined territories.
- Development and Contract manufacturing of Advanced Intermediates (for NCE) for a Japanese MNC.
- Development, scale up and Contract manufacturing of five APIs for a Japanese MNC.

Research & Development

With robust experience of over 30 years, the process research and development team of SCL Lifesciences have proven track record of having executed the synthesis of complex active pharmaceutical ingredients (API) and intermediates. SCL Lifesciences have 100 + highly qualified scientists with strong scientific and academic background with rich experience. Our team excels at resolving complex scientific problems with a systematic approach in a time-bound manner while assuring the quality of all processes and products.



Our experts devise the most effective route for the synthesis of novel/complex intermediate and API's and delivered value added results for various API synthesis and process validations.

Analytical Chemistry team at SCL Lifesciences provides analytical support to process development teams and carry out analytical method validations. Our analytical chemists apply chromatography, spectroscopy, mass spectrometry and nuclear magnetic resonance techniques to a wide range of chemical testing and analysis applications. Using highly sensitive instruments, the team conducts analytical studies at a high level of accuracy and consistency to accelerate the development of complex products.

SCL Knowledge Centre

- With an idea to encourage and enable creativity, SCL has set up a new Knowledge Centre in the hub of Pharmaceuticals in Hyderabad in the Genome Valley.
- The Centre houses development facilities to aid the emerging needs of preventive medicines and to help SCL overcome the volatility caused by worldwide events through parallel development of several Value-added Business streams.
- One of the key verticals at the SCL Knowledge Centre is focused on development of a portfolio of Ingredients /Components for the new applications in the Vaccine industry.
- Over the next few years, this Centre will create a pipeline of products for CDMO/CRO clients, focusing on niche API segments and develop key APIs for SCL's launch portfolio.



Quality Assurance

At SCL Lifesciences we are committed to provide Intermediates & Active Pharmaceutical Ingredients at utmost customer satisfaction through Quality Management System with respect to current Good Manufacturing Practices, by fixing quality objectives and reviewing these periodically for continual improvement.

- Quality Assurance at SCL ensures compliance to National and International Regulatory cGMP requirements.
- The primary responsibility of Quality Assurance is to evaluate and assure the quality of all incoming materials, intermediates and finished products.
- Quality Assurance ensures that the quality systems, manufacturing procedures, warehousing practices and other connected support systems are complying with current Good Manufacturing Practices.
- Qualification / Validation Program are planned throughout the life cycle of the product and facility.
- Computerized systems with potential for impact on product quality are effectively managed under a quality system which is designed to ensure that systems are protected from acts of accidental or deliberate manipulation, modification or any other activity that may impact on data quality and integrity.



Quality Control

We have a Fully equipped in-house laboratory including:

- Wide range of sophisticated 21-CFR-Part-11 compliant analytical instruments.
- Chromatographic instruments are hooked to Empower 3.
- Dedicated microbiological lab.
- Lab is well equipped to comply to upcoming ICH Q3D requirements of "Elemental Impurities" with In-House "ICPMS" and LCMS.



Manufacturing Units

API Facility

- API Plant (ZERO LIQUID DISCHARGE FACILITY)
- 4th US FDA inspection in April 2026. EIR received in June 2026
- EDQM audit cleared in 2024
- AFM by Japanese PMDA, EUGMP, & WHO Geneva GMP compliant
- FDA and TGA Compliant
- Nine (8+1) Pharma blocks of class 100,000 including 2 Pilot and 1 Kilo scale facility
- High pressure reaction vessel block
- No. of reactors: ~108, Capacity: ~271 KL varying from 63 L to 6,000 L
- Capability for multistage, cryogenic reactions & high pressure and temperature reactions.
- Capability under addition – Cyanation

Small Volume Facility

Kilo Scale & Pilot Facility

- Equipment's ranging from 63 L to 1000 L
- Kilo Scale HPAPI (High Potent API) facility
- Dedicated facility for production of low volume and high value APIs
- Facility compliant to cGMP and used for filings in USFDA, PMDA, EDQM, etc.
- Capability for multistage, cryogenic reactions & high-pressure reactions and HPAPIs
- Independent powder processing and finishing area

Intermediate Manufacturing facility

- Largest facility in India for manufacturing of Cephalosporin Inter-mediate
- Large capacity for Bromination (Bromine Handled: 3 MT/ day)
- Capability for multistage, cryogenic reactions & high-vacuum distillation Fully equipped laboratory with HPLC and GCs
- No. of reactors: 28, Capacity: 61 KL varying from 250 L to 5,000 L

Regulatory Approvals

					
USFDA 2015, 2017, 2018, 2026	PMDA AFM Registration 2015	EUGMP 2005, 2008, 2011, 2012, 2015, 2024	TGA Australia 2015, 2025	KOREAN MFDS 2015	WHO GENEVA 2014, 2016, 2019, 2026
					
Health Canada 2020	PMDA 2019	edqm 2024	MEDSAFE NEW ZEALAND MEDICINE AND MEDICAL DEVICES SAFETY AUTHORITY A BUSINESS UNIT OF THE MEDICAL DEVICE INDUSTRY	ANVISA Agência Nacional de Vigilância Sanitária CBPF Approval Year (2023)	NMPA CHINA 2023



API Product List

Product Name	Category	Regulatory Approval / Filing				
		USDMF	CEP/ ASMF	MFDS	ANVISA	Other
Commercial APIs						
Atropine Sulfate	Mydriatic and Cycloplegic	✓	CEP	✓	✓	NMPA TGA, Health Canada
Carglumic Acid	Treatment of Hyperammonaemia	✓				NMPA
Clopidogrel Besylate	Antiplatelet		✓			
Clopidogrel Bisulfate (Form II)	Antiplatelet		CEP	✓		
Dapagliflozin	Type-II Antidiabetic	✓	✓			
Dexketoprofen Trometamol	Analgesic	✓	✓	✓	✓	NMPA, Russia
Diethyl Carbamazine Citrate	Anthelmintic	✓				WHO
Febuxostat	Xanthine Oxidase Inhibitor		✓			
Homatropine Hydrobromide	Anticholinergic medication Mydriatic and Cycloplegic		✓	✓		NMPA
Homatropine Methylbromide	Anticholinergic medication Mydriatic and Cycloplegic	✓	✓		✓	
Ibandronate Sodium	Treatment of Osteoporosis					PMDA, Japan
Ipratropium Bromide	Bronchodilator	✓	CEP	✓	✓	
Ketoprofen	Non-Steroidal Anti-Inflammatory Drug	✓	CEP	✓	✓	Russia, NMPA
Ketoprofen Lysinate	Non-Steroidal Anti-Inflammatory Drug		✓			
Ketorolac Tromethamine	Analgesic		✓	✓	✓	NMPA, Russia, Health Canada, Kenya
Levofloxacin Hemihydrate	Broad Spectrum Antibiotic		CEP			Taiwan, Egypt
Nitisinone	4-hydroxyphenylpyruvate Dioxygenase	✓				
Obidoxime Hydrochloride	Antidote: Acetylcholinesterase Reactivator		✓			
Papaverine Hydrochloride	Erectile Dysfunction	✓		✓		NMPA
Pregabalin	Anticonvulsant Drug					PMDA, Japan
Probenecid	Treatment of Gout and Hyperuricemia	✓				
Ticagrelor	Antiplatelet		✓			
Tiotropium Bromide Monohydrate	Bronchodilator		CEP	✓		
Vildagliptin	Anti-Hyperglycemic Agent		✓		✓	

Disclaimer: Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes a patent infringement. The liability of any sale into such protected markets is at buyer's risk.



API Product List

APIs Launching

- **Empagliflozin** Q2 2026
Antidiabetic
- **Tribenoside** Q2 2026
Anti-inflammatory drug primarily used to treat Hemorrhoids
- **Bempedoic acid** Q3 2026
Lipid Lowering Agent
- **Tafamidis Base** Q3 2026
Transthyretin kinetic stabilizer
- **Daprodustat** Q4 2026
Treatment of Anaemia due to CKD
- **Ozanimod** Q4 2026
Treatment of relapsing multiple sclerosis and ulcerative colitis

APIs Under Pipeline

- **Atogepant**
Oral CGRP antagonist; Anti-migraine
- **Cenobamate**
Anticonvulsant
- **Edoxaban Tosylate**
Direct oral anticoagulants (DOACs)
- **Fezolinetant**
Treatment of moderate to severe vasomotor symptoms due to menopause
- **Isavuconazonium Sulfate**
Azole antifungals
- **Ivacaftor**
Cystic Fibrosis Transmembrane conductance Regulator (CFTR)
- **Solriamfetol HCL**
Dopamine and norepinephrine reuptake inhibitor (DNRI)
- **Sparsentan**
Genitourinary Agent (Reduce proteinuria in adults with primary immunoglobulin A nephropathy)
- **Upadacitinib Hemihydrate**
Janus kinase (JAK)1-selective inhibitor
- **Vibegron**
Treatment of overactive bladder
- **Vonoprazan**
Potassium-competitive acid blockers (PCAB)

Disclaimer: Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes a patent infringement. The liability of any sale into such protected markets is at buyer's risk.



Pharmaceutical Intermediates

Aripiprazole Lauroxil Intermediate	Chloro Methyl Laurate [61413-67-0] Aripiprazole Lauroxil intermediates
Carbapenem Intermediate	4-Nitrobenzyl Diazoacetoacetate [82551-63-1] Imipenem intermediate
Cephalosporin Intermediates	(z)-4-Bromo-2-methoxyimino-3-oxobutyric acid [79232-66-9] Cefpodoxime Proxetil Intermediate
	(z)-4-Chloro-2-methoxyimino-3-oxobutyric acid [111230-59-2] Cefpodoxime Proxetil intermediate
	4-Nitrobenzyl Bromide [100-11-8] Cefaclor intermediate
Dapagliflozin Intermediates	1-(4-bromo-2-chlorobenzyl)-3-ethoxybenzene [1996-30-1]
	Tetramethyl silyl gluconolactone [32384-85-9]
Epalrestat Intermediate	Alpha Methyl cinnamaldehyde [101-39-3]
Eprosartan Intermediates	diethyl 2-((thiophen-2-yl)methylene)malonate [60-29-7]
	diethyl 2-((thiophen-2-yl)methyl)malonate [26420-00-8]
Ketoprofen Intermediate	ethyl 3-(1-cyanoethyl)benzoate [64-17-5]
Lisinopril Intermediate	L-Proline Benzyl Ester Hydrochloride [16652-71-4]
Tiotropium Intermediate	Scopine di (2-thienyl) glycolate [136310-64-0]
Valsartan Intermediate	4-(Bromo Methyl) Biphenyl-2-Carbonitrates [114772-54-2]
Zopiclone Intermediate	6-(5-Chloropyrid-2-yl)-5-hydroxy-7-oxo-5, 6-dihydropyrrolo [3, 4-b] pyrazine [43200-81-3]
Other Intermediates	5-Chlorosalicylic amide [37893-37-1]
	1-(2-Ethoxyethyl) benzimidazolone [101953-61-1]
	Para bromobenzaldehyde [1122-91-4]
	4-Nitrobenzyl Alcohol [619-73-8]

SCL Lifesciences Limited

Head Office

370 Phase-II, Industrial Area,
Panchkula, Haryana – 134 109, India
Tel : +91 172 5054817 / 5054818

API Facility

Bhagwanpura, Derabassi-Barwala Road
Derabassi, Sahibzada Ajit Singh Nagar
Punjab – 140 507, India
Tel : +911762506091/ 530300
Email : internationalsales@scllifesciences.com

Intermediates Facility

Village Saidpura, Derabassi- Barwala Road
Derabassi, Sahibzada Ajit Singh Nagar
Punjab – 140 507, India
Tel : +91 1762522312/ 522314
Email : domesticsales@scllifesciences.com

Marketing Headquarters

5th Floor, Carnoustie Tower 19 A,
Sec 16A, Noida, UP – 201 301, India
Tel : +91 120 4177204
Email : anil.srivastava@scllifesciences.com
monimekhala.dey@scllifesciences.com